Literature DB >> 24080479

Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model.

Emma Rey-Jurado1, Griselda Tudó, Dolors Soy, Julian González-Martín.   

Abstract

Multidrug resistance is a problem in the management of tuberculosis, creating an urgent need for new regimens including currently available drugs. Macrophage models allow an evaluation of the effect of drugs against intracellular bacilli. The effect of the following different drug combinations against six multidrug-resistant and six drug-susceptible clinical isolates of Mycobacterium tuberculosis multiplying inside the human macrophage THP-1 cell line was studied: levofloxacin/linezolid/ethambutol; levofloxacin/amikacin/ethambutol; and levofloxacin/linezolid/amikacin. Macrophages were lysed, seeded onto Middlebrook 7H11 plates and CFU were counted after 21 days of incubation. The interaction of the drugs in combination was interpreted by the effect of the combination compared with the most active single drug alone. The antimicrobial activity of the drugs was evaluated comparing the log(10)CFU/well of the isolate with and without the drug. Drug concentrations within infected macrophages and in extracellular medium were simultaneously determined by chromatography. The levofloxacin/linezolid/amikacin and levofloxacin/linezolid/ethambutol combinations showed antagonism against most of the isolates (91.7%) after a 4-day protocol, whereas levofloxacin/amikacin/ethambutol displayed indifference. Levofloxacin alone and levofloxacin/amikacin/ethambutol were the most potent antimicrobials, presenting reductions up to 5.49 log(10) and 5.86 log(10), respectively. The drug penetration percentages ranged from 5.46% to 11.10%. Intracellular concentrations for the drug alone compared with those for the drugs in combination were not significantly different. All of the combinations tested against M. tuberculosis-infected macrophages showed antimicrobial activity, with combinations including linezolid and levofloxacin showing an antagonistic effect that may be explained by efflux transporters or changes in the macrophage environment.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Macrophage; Multidrug resistance; Mycobacterium tuberculosis; Second-line drugs

Mesh:

Substances:

Year:  2013        PMID: 24080479     DOI: 10.1016/j.ijantimicag.2013.07.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Carleton M Sherman; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

2.  Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.

Authors:  Flavia Sorrentino; Ruben Gonzalez del Rio; Xingji Zheng; Jesus Presa Matilla; Pedro Torres Gomez; Maria Martinez Hoyos; Maria Esther Perez Herran; Alfonso Mendoza Losana; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

Review 3.  Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.

Authors:  Anne Lenaerts; Clifton E Barry; Véronique Dartois
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

4.  Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Authors:  Matthew Zimmerman; Jodi Lestner; Brendan Prideaux; Paul O'Brien; Isabela Dias-Freedman; Chao Chen; Jillian Dietzold; Isaac Daudelin; Firat Kaya; Landry Blanc; Pei-Yu Chen; Steven Park; Padmini Salgame; Jansy Sarathy; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium abscessus Infection.

Authors:  Noemi Poerio; Camilla Riva; Daniela M Cirillo; Maurizio Fraziano; Tommaso Olimpieri; Marco Rossi; Nicola I Lorè; Federica De Santis; Lucia Henrici De Angelis; Fabiana Ciciriello; Marco M D'Andrea; Vincenzina Lucidi
Journal:  Microbiol Spectr       Date:  2022-01-26

6.  Drug concentration at the site of disease in children with pulmonary tuberculosis.

Authors:  Elisa Lopez-Varela; Ahmed A Abulfathi; Natasha Strydom; Pierre Goussard; Abraham C van Wyk; Anne Marie Demers; Anneen Van Deventer; Anthony J Garcia-Prats; Johannes van der Merwe; Matthew Zimmerman; Claire L Carter; Jacques Janson; Julie Morrison; Helmuth Reuter; Eric H Decloedt; James A Seddon; Elin M Svensson; Rob Warren; Radojka M Savic; Véronique Dartois; Anneke C Hesseling
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

7.  Antibiotics induce polarization of pleural macrophages to M2-like phenotype in patients with tuberculous pleuritis.

Authors:  Sisi Wang; Jian Zhang; Liyan Sui; Hao Xu; Qianling Piao; Ying Liu; Xinglong Qu; Ying Sun; Lei Song; Dan Li; Liping Peng; Shucheng Hua; Guangan Hu; Jianzhu Chen
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.